8:00-17:30, Saturday 13th May, Centre Mont-Royal, 2200 Rue Mansfield, Montréal, QC H3A3R8, Canada
The development of highly-effective, well-tolerated direct acting antiviral (DAA) hepatitis C (HCV) regimens with cure rates >95% is one of the major advances in recent medicine, providing an opportunity to reverse the rising burden of advanced liver disease and HCV-related mortality.
People who inject drugs (PWID) account for the majority of new (90%) and existing (65-70%) cases of HCV in many high- and middle-income countries. As such, drug and alcohol settings are logical venues for integrating HCV care.
Led by the International Network on Hepatitis in Substance Users (INHSU) in collaboration with Harm Reduction International, Médecins du Monde, the Canadian Network on Hepatitis C, Canadian Research Initiative in Substance Misuse, National Viral Hepatitis Roundtable, CATIE, and the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine, the Hepatitis C Satellite Symposium will be an innovative, cutting edge meeting of clinicians, public health professionals, government, community and primary care representatives and most importantly people living with hepatitis C, committed to integrating successful care of drug use and HCV among PWID.
The morning plenary session, led by an esteemed panel of international speakers, will include presentations on linkages to HCV prevention and care in drug and alcohol settings and changes to drug policy that are needed to achieve HCV elimination.
The afternoon will feature two concurrent interactive sessions. The first workshop, “Preparing patients for interferon-free therapy in drug and alcohol settings: An education and training workshop for drug and alcohol practitioners” led by INHSU, will include a combination of presentations and group-based case study discussions providing practitioners with the practical skills with which to treat HCV in their setting.
The parallel discussion session “How can researchers, practitioners, policy makers, and the community work together to improve access to HCV care for people who inject drugs?” will include discussion of strategies for addressing reimbursement restrictions to DAA therapy and models of care showcasing how we can best work together to deliver successful HCV prevention and treatment.
Please join us for what is sure to be an engaging and informative day. Register for free.
Morning and afternoon tea, lunch and refreshments are included.